AI's Next Frontier: Dyno Unlocks Smarter Gene Therapy Delivery

WATERTOWN, Mass. – April 27, 2026 – A fundamental challenge has long constrained the revolutionary promise of gene therapy: how to safely and precisely deliver a genetic payload to the right cells in the body while avoiding others. This May, at the world’s preeminent gene therapy conference, one company aims to prove that the answer lies in artificial intelligence.

Dyno Therapeutics, a Cambridge-based genetic technologies firm, is poised to make a significant impact at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Boston. The company will present a wealth of new data showcasing its AI-powered platform, which designs novel adeno-associated virus (AAV) capsids—the protein shells that act as delivery vehicles for gene therapies—engineered for superior performance. The upcoming presentations signal a potential leap forward in creating more effective treatments for devastating neuromuscular and central nervous system (CNS) disorders.

The AI-Powered Revolution in Delivery

For years, gene therapy has relied on a limited toolkit of naturally occurring AAVs. While effective in some cases, these natural vectors often fall short. They can trigger immune responses, deliver their cargo to the wrong organs like the liver—leading to toxicity at high doses—and fail to efficiently reach critical targets like muscle or the brain. This has created a therapeutic ceiling, limiting dose levels and patient eligibility.

Dyno's approach is to break through that ceiling not by tweaking existing AAVs, but by designing entirely new ones from the ground up. The company’s platform integrates high-throughput in vivo experimentation with sophisticated machine learning models. By generating and analyzing massive datasets on how millions of capsid variations perform inside living systems, its AI can learn the complex rules of AAV biology and then predict and design novel capsids with optimized properties.

“Dyno applies AI to create better technologies for gene delivery and sequence design,” stated Eric Kelsic, Ph.D., CEO and Cofounder of Dyno Therapeutics, in the company’s announcement. He will elaborate on these advances during a special Scientific Symposium, highlighting the company's AI-powered sequence design platform and its mission to accelerate the development of safe and effective gene therapies.

This AI-first methodology is a key differentiator in a competitive field. While other companies use advanced screening or rational design, Dyno’s emphasis on de novo design allows it to explore a vast, uncharted landscape of potential AAV sequences, generating solutions that might never be discovered through traditional methods.

Targeting the Untreatable: Breakthroughs for Muscle and Brain

The data set for presentation at ASGCT provides compelling evidence of the platform's power. Two oral presentations will focus on a next-generation capsid for neuromuscular diseases, demonstrating “significantly enhanced muscle tropism with reduced liver biodistribution at low doses” in non-human primates (NHPs). This dual achievement is critical. Enhanced muscle targeting means more of the therapeutic payload reaches its intended destination, potentially increasing efficacy for diseases like Duchenne muscular dystrophy or limb-girdle muscular dystrophies. Simultaneously, reducing accumulation in the liver—a common site of AAV-related toxicity—could dramatically improve the safety profile and allow for effective treatment at lower, safer doses.

Equally impressive are the planned poster presentations on novel CNS-targeting capsids. One abstract details a capsid that achieves “near complete CNS delivery in humanized TfR1 mice with exceptional liver detargeting.” Another highlights a capsid with “broad CNS transduction and improved cross-species tropism” in both rodents and NHPs. Overcoming the blood-brain barrier to deliver therapies throughout the central nervous system is one of the toughest challenges in medicine. These results suggest Dyno’s AI-designed vectors could pave the way for new treatments for neurodegenerative conditions like Huntington's disease, genetic forms of ALS, and various lysosomal storage disorders that affect the brain.

An invited talk by Adrian Veres, M.D., Ph.D., titled “AI-guided design of bispecific AAVs for targeted delivery,” further points to the sophistication of the company's platform, suggesting an ability to engineer capsids with multiple, highly specific functions.

Strategic Partnerships as a Force Multiplier

Dyno is not aiming to take dozens of drugs to market on its own. Instead, its business model positions it as a foundational technology enabler for the entire gene therapy industry. This strategy is validated by a series of high-profile collaborations that pair its AI platform with the clinical and commercial power of pharmaceutical giants.

A partnership with Roche is focused on developing next-generation capsids for CNS diseases and liver-directed therapies, leveraging Roche's deep expertise in neuroscience. A separate collaboration with Astellas aims to create novel vectors for genetic medicines targeting skeletal and cardiac muscle, including for ophthalmic diseases. These alliances provide Dyno with significant funding and a clear path to translate its engineered capsids into clinical candidates, while allowing its partners to supercharge their gene therapy pipelines.

Beyond pharma, a crucial partnership with technology leader NVIDIA underscores Dyno's identity as a cutting-edge AI company. This collaboration provides access to the state-of-the-art computing hardware and software expertise needed to run its massive-scale simulations and train increasingly complex machine learning models, ensuring its platform remains at the forefront of computational biology.

The Promise and Ethics of 'Genetic Agency'

Driving Dyno's scientific and commercial strategy is a core mission encapsulated in the term “Genetic Agency.” The company defines this as an individual’s ability to take action at the genetic level to live a healthier life. The concept reframes gene therapy from a last-resort intervention to an empowering tool that gives patients proactive control over their genetic destiny.

This vision of patient empowerment is widely celebrated by patient advocates and clinicians who have long sought more effective options for devastating genetic conditions. By creating safer and more potent therapies, the technology could expand treatment to patients previously excluded due to pre-existing immunity or risk of side effects. However, the increasing power of these technologies also brings profound societal questions into focus. Bioethicists caution that true agency depends on equitable access, ensuring these transformative treatments do not become available only to the wealthy.

“The ultimate test of this new 'agency' will be whether it's available to everyone, not just a select few,” one bioethicist noted in a recent industry discussion. As the technology moves from the theoretical to the practical, ensuring broad and fair access will be as critical as the scientific innovation itself.

As the gene therapy world converges on Boston, the presentations from Dyno Therapeutics will be among the most closely watched. They represent more than just promising data; they are a demonstration of how artificial intelligence is being harnessed to solve biology's most complex delivery problems, moving the ambitious goal of precise, powerful, and accessible genetic medicine closer to a tangible reality.